Biomedicine. Back to an aspirin a day?
Vane
John R
JR
William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London EC1M 6BQ, UK.
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D020212:Carotid Artery Injuries / Q000473:pathology; D002455:Cell Division; D002986:Clinical Trials as Topic; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D011464:Epoprostenol / Q000378:metabolism*; D006706:Homeostasis; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D007783:Lactones / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D008565:Membrane Proteins; D051379:Mice; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D009203:Myocardial Infarction / Q000453:epidemiology; D009288:Naproxen / Q000627:therapeutic use; D015539:Platelet Activation / Q000187:drug effects*; D011451:Prostaglandin-Endoperoxide Synthases; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin / Q000235:genetics / Q000378:metabolism; D017482:Receptors, Thromboxane / Q000235:genetics / Q000378:metabolism; D013450:Sulfones; D013928:Thromboxane A2 / Q000378:metabolism*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013450:Sulfones; C116926:rofecoxib; D013928:Thromboxane A2; D009288:Naproxen; D011464:Epoprostenol; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; C496512:Ptgs1 protein, mouse